A 1 Year Randomized, Controlled, Open-Label Study of the Impact of Flexible Doses of Niacin (Niaspan) as an Adjunct To Antipsychotic Medication in the Treatment of First Episode Psychosis.

Trial Profile

A 1 Year Randomized, Controlled, Open-Label Study of the Impact of Flexible Doses of Niacin (Niaspan) as an Adjunct To Antipsychotic Medication in the Treatment of First Episode Psychosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2015

At a glance

  • Drugs Niacin (Primary) ; Antipsychotics
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Aug 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 06 Aug 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 01 Nov 2012 Planned end date changed from 1 Jan 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top